Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer
OUTLOOK THERAPEUTICS INC.
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the identification, development, manufacture, and commercialization of complex biosimilar therapeutics. It focuses on monoclonal antibodies, in the disease areas of immunology and oncology.
Sign Up for our 100% Free Email Newsletter:
Text Message Alerts ---> text 'PS101' to 67076
(It's FREE, however Msg&Data rates may apply.)